An observational study in Subjective Cognitive Decline (SCD), Functional Cognitive Disorder and Alzheimer's Disease, sponsored by University of Milano Bicocca. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by University of Milano Bicocca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.
Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 8th largest by planned enrollment of the 36 observational ones that give a count, is one of 11 that started in 2026, is one of 36 observational ones, reaches primary completion later than 45 of the 71 other live ones, and was the 194th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
University of Siena · Sites in Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 47 · Phase 3 75 · Phase 4 2
First in 2003; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 328 across the 170 interventional studies, 273 across the 36 observational. Of the 125 that completed or were terminated, 64 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 206 have an industry lead sponsor. The 10 most frequent:
University of Milano Bicocca is the lead sponsor of 126 studies on the registry; 47 are open to participants now.
University of Milano Bicocca has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Alzheimer Disease with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06179680IRCCS Policlinico S. DonatoWhite Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease | 2026-12 |
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 206 studies in Alzheimer Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter prospective observational cohort study is to better understand the clinical, neuropsychological, and biological characteristics of individuals attending Brain Health Services (BHS) in the Lombardy region. The study focuses on adults with subjective cognitive decline (SCD), functional cognitive disorder (FCD), or "well worried" individuals without objective cognitive impairment.
The main questions it aims to answer are:
Participants will:
The study plans to enroll approximately 1000 participants across multiple BHS in Lombardy and will follow them for a total duration of 7 years. The results will help clarify the role of biomarkers in early cognitive complaints and support the development of preventive strategies within BHS.
Subjects accessing BHS in Lombardy with SCD, FCD or "well worried" individuals without objective cognitive impairment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with either Subjective Cognitive Decline, Functional Cognitive Disorder or Well Worried accessing Brain Health Services for dementia risk assessment
Clinical, neuropsychological, and biological patterns associated with AD plasma biomarker positivity at baseline
Identification of multivariate patterns (e.g., principal component analysis and clustering methods) differentiating individuals positive versus negative for Alzheimer's disease plasma biomarker (p-tau217) at baseline, based on demographic, clinical, neuropsychological, radiological, and biological variables.
Time frame: Baseline (first visit at Brain Health Service)
Psychological impact of biomarker disclosure at1 week
Change in psychological measures (Hospital Anxiety and Depression Scale - HADS; Impact of Event Scale - Revised - IES-R) before and one week after communication of biomarker results.
Time frame: Baseline (pre-disclosure) and 1 week after biomarker disclosure
Predictors of AD plasma biomarker positivity at baseline
Identification of demographic, clinical, neuropsychological, and radiological predictors of baseline AD plasma biomarker positivity, assessed using logistic and regression models.
Time frame: Baseline
Predictors of longitudinal changes in AD biomarkers
Identification of clinical, neuropsychological, and radiological predictors of longitudinal changes in plasma AD biomarkers over time using linear mixed-effects models.
Time frame: Baseline through 5 years follow-up
Predictors of conversion to MCI or dementia
Evaluation of clinical, biological (plasma and CSF biomarkers), radiological, and neuropsychological predictors of progression to mild cognitive impairment (MCI) or dementia using survival analysis (Kaplan-Meier and Cox models).
Time frame: Baseline through 5 years follow-up
Predictive performance of plasma biomarkers for AD diagnosis
Assessment of diagnostic accuracy of plasma biomarkers (neurodegeneration, Alzheimer's pathology, neuroinflammation markers) in predicting CSF biomarker positivity for AD using logistic regression models and ROC curve analysis.
Time frame: Baseline
Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (including demographic, clinical, neuropsychological, biomarker, and imaging-derived variables) will be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Beginning 12 months after primary publication and ending 5 years thereafter.
Access criteria: Data will be available to researchers who provide a methodologically sound proposal, subject to approval by the study steering committee and signing of a data use agreement.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 24 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milano Bicocca →